Tiziana Triulzi
Overview
Explore the profile of Tiziana Triulzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agresti R, Sandri M, Capri G, Bianchi G, Triulzi T, Lozza L, et al.
Br J Surg
. 2025 Mar;
112(3).
PMID: 40042985
Background: The role of axillary surgery in breast cancer has shifted over time from a therapeutic operation to a staging method for subsequent adjuvant therapies, through the introduction of sentinel...
2.
Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):19.
PMID: 39833955
Background: Growing evidence shows that the reprogramming of fatty acid (FA) metabolism plays a key role in HER2-positive (HER2 +) breast cancer (BC) aggressiveness, therapy resistance and cancer stemness. In...
3.
Sommariva M, Dolci M, Triulzi T, Ambrogi F, Dugo M, De Cecco L, et al.
Sci Rep
. 2024 Jun;
14(1):13134.
PMID: 38849411
The pandemic of coronavirus disease 19 (COVID-19), caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2), had severe repercussions for breast cancer patients. Increasing evidence indicates that SARS-CoV-2 infection may directly...
4.
Rybinska I, Mangano N, Romero-Cordoba S, Regondi V, Ciravolo V, De Cecco L, et al.
Int J Cancer
. 2024 Jan;
154(10):1842-1856.
PMID: 38289016
Triple negative breast cancers (TNBC) are characterized by a poor prognosis and a lack of targeted treatments. Their progression depends on tumor cell intrinsic factors, the tumor microenvironment and host...
5.
Bernardo G, Le Noci V, Di Modica M, Montanari E, Triulzi T, Pupa S, et al.
Cells
. 2023 Aug;
12(15).
PMID: 37566024
Emerging evidence suggests a profound association between the microbiota composition in the gastrointestinal tract and breast cancer progression. The gut microbiota plays a crucial role in modulating the immune response,...
6.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37286305
Background: Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) <50%. Although single-agent pembrolizumab has also demonstrated some activity...
7.
Prelaj A, Ganzinelli M, Trovo F, Roisman L, Pedrocchi A, Kosta S, et al.
Clin Lung Cancer
. 2023 Mar;
24(4):381-387.
PMID: 36959048
Although immunotherapy (IO) has changed the paradigm for the treatment of patients with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50% of treated patients experience a long-term...
8.
Bernardo G, Le Noci V, Ottaviano E, De Cecco L, Camisaschi C, Guglielmetti S, et al.
Cancer Lett
. 2022 Dec;
555:216041.
PMID: 36565918
The mammary gland hosts a microbiota, which differs between malignant versus normal tissue. We found that aerosolized antibiotics decrease murine mammary tumor growth and strongly limit lung metastasis. Oral absorbable...
9.
Indino S, Borzi C, Moscheni C, Sartori P, De Cecco L, Bernardo G, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555441
Hyperprogressive disease (HPD), an aggressive acceleration of tumor growth, was observed in a group of cancer patients treated with anti-PD1/PDL1 antibodies. The presence of a peculiar macrophage subset in the...
10.
Triulzi T, Regondi V, Venturelli E, Gasparini P, Ghirelli C, Groppelli J, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428742
While the results thus far demonstrate the clinical benefit of trastuzumab in breast cancer (BC), some patients do not respond to this drug. HER2 mRNA, alone or combined with other...